The company’s lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback